Seaport Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Seaport Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Seaport Therapeutics, Inc. Common Stock (SPTX) has a cash flow conversion efficiency ratio of -0.062x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.14 Million) by net assets ($422.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Seaport Therapeutics, Inc. Common Stock (2024–2025)
Cash flow conversion efficiency of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Seaport Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Seaport Therapeutics, Inc. Common Stock share price for real-time trading data and today's change.
Seaport Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Seaport Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Seaport Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seaport Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see how much is Seaport Therapeutics, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
0.014x |
|
Guangzhou Goaland Energy Conservation Tech Co Ltd
SHE:300499
|
0.027x |
|
Zhongnanhong Culture Group Co Ltd
SHE:002445
|
0.032x |
|
Dorian LPG Ltd
NYSE:LPG
|
0.044x |
|
Growthpoint Properties Australia
AU:GOZ
|
0.031x |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
-0.020x |
|
Guangzhou Metro Design And Research
SHE:003013
|
0.029x |
|
Black Diamond Group Limited
TO:BDI
|
0.040x |
Annual Cash Flow Conversion Efficiency for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. Review Seaport Therapeutics, Inc. Common Stock leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-92.55 Million | $-77.94 Million | 0.842x | -29.37% |
| 2024-12-31 | $-24.85 Million | $-29.63 Million | 1.192x | -- |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more